

17 October 2024

Cleansing Notice



NOTICE PURSUANT TO PARAGRAPH 708A(5)(e) OF THE CORPORATIONS ACT 2001

This notice is given by Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (“Act”).


The Company advises that on 17 October 2024 it applied for quotation of 1,112,389 fully paid ordinary shares as consideration for services as detailed in the ASX announcement dated 17 October 2024.

LGP gives notice that:

1. the Shares were issued without disclosure under Part 6D.2 of the Corporations Act;
2. as at the date of this notice the Company has complied with the provision of Chapter 2M of the Corporations Act as they apply to the Company; and section 674 of the Corporations Act;
3. as at the date of this notice there is no excluded information required to be disclosed under section 708A(6)(e) of the Corporations Act.

Notwithstanding this, LGP notes that in its ordinary course of business it is continually working with prospective customers and potential suppliers and targets on active proposals including supply, offtake and acquisition proposals, some of which may, in the future, prove to be material and potentially price sensitive. In the event that any such proposals become sufficiently certain or material enough to warrant disclosure to the market, the Company will comply with its disclosure obligations at that time. The Company also notes that its September Quarterly & 4C will disclose a quarterly revenue of \$10.2 million and cash receipts of \$10.8 million representing 40% and over 30% increases respectively on the prior quarter and a positive cashflow of \$0.4 million for the quarter.

**ENDS
BY ORDER OF THE BOARD**



Alistair Warren
Company Secretary



For further information please contact:

Alistair Warren
Company Secretary
Little Green Pharma
E: cosec@lgpharma.com.au
T: +61 8 6280 0050

Paul Long
Chief Executive Officer
Little Green Pharma
E: p.long@lgp.global
T: +61 8 6280 0050

About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges medicinal cannabis products, with its Danish facility being one of the largest medicinal cannabis production sites in Europe (if not the largest) and its West Australia site a premium indoor production facility specialising in premium hand-crafted cannabis strains.

Little Green Pharma products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp

LGP's Cannabis Wrap

LGP's Cannabis Wrap offers insights on global cannabis markets with links to key news and developments from around the world

Sign up to LGP's Cannabis Wrap here: <https://investlittlegreenpharma.com/site/contact/newsletter-sign-up>